ArentFox Schiff

As of May 12, 2026

ArentFox Schiff LLP is a full-service "BigLaw" firm with a substantial US footprint, including offices in Washington, D.C., New York, Chicago, and Los Angeles. The firm resulted from the 2022 merger of Arent Fox and Schiff Hardin. It is regularly listed among the top 100 US law firms by revenue, ranking 91st in the 2026 AmLaw 100 survey. While a general practice firm, it maintains a nationally recognized intellectual property group with capabilities in patent, trademark, and copyright law. The firm's patent practice includes more than 70 full-time professionals, many with advanced technical degrees.

The firm’s patent litigation practice has a notable specialty in the life sciences sector, particularly representing generic pharmaceutical manufacturers in Hatch-Waxman (ANDA) litigation. In addition to its significant pharmaceutical and medical device work, the practice handles disputes across a range of other technologies, including consumer electronics, telecommunications, software, and automotive parts. The firm represents clients in various forums, including federal district courts across the US, the U.S. International Trade Commission (ITC), and the Federal Circuit.

Based on available data and the firm's own reporting, the practice appears well-balanced but is frequently highlighted for its work defending operating companies, particularly generic drug makers and companies targeted by non-practicing entities (NPEs). A notable recent matter includes the firm's representation of defendant Oura Health Oy, a manufacturer of smart rings, in litigation brought by Zepp Inc. The firm also touts its success in securing a complete victory at the ITC for a fashion brand, obtaining a general exclusion order to block infringing footwear imports. In another publicly reported outcome, the firm obtained a summary judgment of invalidity for client Nexus Pharmaceuticals in a case concerning a liquid formulation for a cancer drug.

ArentFox Schiff maintains a significant practice before the Patent Trial and Appeal Board (PTAB), representing clients in inter partes review (IPR) and post-grant review (PGR) proceedings. The firm’s attorneys publish analyses of PTAB trends and have secured notable wins, including a rare reversal of a patent examiner's subject matter eligibility rejection for a fintech client. The patent litigation practice is co-led by Janine A. Carlan and Sailesh K. Patel. Carlan is frequently recognized for her work in Hatch-Waxman and ITC cases and has been named among the top women at the PTAB bar. Other key partners recognized by industry publications include Imron T. Aly and Matthew T. Wilkerson.